Tanespimycin + Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma: Final Results of a Phase 1/2 Study PG Richardson, 1 A Chanan-Khan, 2 S Lonial, 3 A Krishnan, 4 M Carroll, 5 M Alsina, 6 M Albitar, 7 D Berman, 8 S Kaplita, 8 KC Anderson 1 1 Dana-Farber Cancer Institute, Boston, MA, USA; 2 Roswell Park Cancer Institute, Buffalo, NY, USA; 3 Emory University, Winship Cancer Institute, Atlanta, GA, USA; 4 City of Hope, Duarte, CA, USA; 5 Sutter Regional Cancer Institute, Sacramento, CA, USA; 6 H. Lee Moffitt Cancer Center, Tampa, FL, USA; 7 Quest Hematopathology, San Juan Capistrano, CA, USA; 8 Bristol-Myers Squibb, Princeton, NJ, USA